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Abstract: Background: Chorea-acanthocytosis (ChAc) is a rare hereditary neurodegenerative disease
with deformed red blood cells (RBCs), so-called acanthocytes, as a typical marker of the disease.
Erythrocyte sedimentation rate (ESR) was recently proposed as a diagnostic biomarker. To date, there
is no treatment option for affected patients, but promising therapy candidates, such as dasatinib,
a Lyn-kinase inhibitor, have been identified. Methods: RBCs of two ChAc patients during and
after dasatinib treatment were characterized by the ESR, clinical hematology parameters and the
3D shape classification in stasis based on an artificial neural network. Furthermore, mathematical
modeling was performed to understand the contribution of cell morphology and cell rigidity to the
ESR. Microfluidic measurements were used to compare the RBC rigidity between ChAc patients and
healthy controls. Results: The mechano-morphological characterization of RBCs from two ChAc
patients in an off-label treatment with dasatinib revealed differences in the ESR and the acanthocyte
count during and after the treatment period, which could not directly be related to each other.
Clinical hematology parameters were in the normal range. Mathematical modeling indicated that
RBC rigidity is more important for delayed ESR than cell shape. Microfluidic experiments confirmed
a higher rigidity in the normocytes of ChAc patients compared to healthy controls. Conclusions: The
results increase our understanding of the role of acanthocytes and their associated properties in the
ESR, but the data are too sparse to answer the question of whether the ESR is a suitable biomarker
for treatment success, whereas a correlation between hematological and neuronal phenotype is still
subject to verification.
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1. Introduction
Chorea-acanthocytosis (ChAc) is a rare hereditary autosomal recessive neurodegener-
ative disease, caused by mutations in the VPS13A gene [1]. A portion of the red blood cells
(RBCs) has the pathological shape of acanthocytes [2]. Symptom onset usually occurs in the
third to fourth decades [3]. The interconnections between mutations, neurodegeneration
and the role of the RBCs is largely elusive. In particular, it is unknown to what extent
the neurological phenotype and its individual longitudinal progression may or may not
be related to hematological parameters, including acanthocyte number and erythrocyte
sedimentation rate [2]. However, it was found that in RBCs and iPS-derived neurons, the
activity of Lyn-kinase is significantly increased [4], which was proposed to contribute to
the pathophysiology of the disease [1]. Therefore, Lyn-kinase inhibitors, such as dasatinib,
have moved into the focus of ChAc research. This point of view is substantiated by in vitro
investigations of human RBCs [4] as well as by systemic investigations of a ChAc mouse
model [5].
A first off-label approach with dasatinib indicated target engagement at least in red
blood cells but—potentially due to slow disease progression—did not reveal clear treatment
effects in the central nervous system [6]. Due to mild gastrointestinal side effects [7], a
second treatment period with a reduced dose (from 100 to 80 mg/day) was performed.
Considering diagnosis, ChAc is often diagnosed late and is also prone to misdiagnosis
due to, e.g., (i) the difficulty to identify acanthocytes in the blood smears [8] and (ii) the
fact that approximately 10% of the patients do not show acanthocytes at all [9]. The
prevalence of approximately 1:1,000,000 is not in favor of increasing awareness of the
disease. Recently, we reported the usefulness of the ESR as a diagnostic marker. We
observed that the ESR is not increased but lowered, in contrast to the common effect of
inflammatory diseases. Another deviation from classical ESR parameters is the preferential
reading after a sedimentation time of two hours instead of the conventional one hour. We
also had the chance to analyze blood samples from the second dasatinib treatment period
and compare them to samples which were taken after the end of this treatment period.
The aim of this study was to test, as previously proposed [10], whether the ESR can be
used as a biomarker to monitor treatment response of dasatinib and to explain the influence
of particular plasma components and cellular properties on a putative change in the ESR.
2. Materials and Methods
2.1. Blood Collection
Blood samples were collected from ChAc patients and healthy control persons. Pa-
tients were being treated at the Department of Neurology of Technische Universität Dres-
den. The diagnosis of ChAc was based on the clinical phenotype and was confirmed
by detection of VPS13A mutations and by chorein Western blot [11]. Blood sample col-
lection was approved by the “Ärztekammer des Saarlandes”, ethics votum 51/18, and
performed after informed consent was obtained according to the Declaration of Helsinki.
Blood was taken in the morning during routine patient visits and immediately transported
to Saarland University in Homburg and Saarbrücken for further analysis, which started
6 to 8 h after withdrawal. Since transportation can have a tremendous effect on blood
parameters [12,13], samples from the patients’ mother and one of the investigators were
taken as transportation controls.
2.2. Dasatinib Treatment
Two ChAc patients (P1 and P2, Supplementary Table S1) were treated off-label with
the FDA-approved tyrosine kinase inhibitor (TKI) dasatinib (DRKS00023177). Diagnosis
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was confirmed by chorein Western blot and genetic testing long before the study was
initiated during clinical routine. The patients gave their informed consent for the off-label
treatment with dasatinib. The dose of 80 mg dasatinib per day was administered orally.
Evaluation of the off-label treatment primarily included monitoring of potential adverse
reactions or events, as well as outcome assessments in the context of routine care adjusted
to the clinical phenotype (see Reference [6]) initially every 2 weeks and after 8 weeks of
treatment monthly/bimonthly.
2.3. Determination of the Erythrocyte Sedimentation Parameters
Erythrocyte sedimentation rate (ESR) measurements were performed in standard
Westergren tubes (Dispette original, REF GS1500) of 200 mm height with Ethylene Diamine
Tetraacetic Acid (EDTA) blood. Color pictures of the tubes were automatically taken
every minute with a Canon EOS 500D camera for up to 50 h to cover the whole range of
sedimentation in every case. For each tube, a custom-written MATLAB algorithm extracted
the position of the interface at the top of the concentrated erythrocyte suspension with an
accuracy of at least 0.1 mm.
2.4. Selection and Determination of Clinical Laboratory Parameters
Measurements of clinical laboratory parameters were performed by standard methods
in the Clinical Chemistry Laboratory of Saarland University Hospital (Homburg, Ger-
many). Since a previous study identified both RBC properties and plasma constituents as
contributors to a delayed ESR [10], we tested routine RBC and plasma parameters. RBC-
related parameters tested were hematocrit, RBC number, hemoglobin concentration, mean
cellular volume (MCV), mean cellular hemoglobin (MCH) and mean cellular hemoglobin
concentration (MCHC). The blood plasma parameters we analyzed were parameters that
we could at least slightly relate to RBC aggregation, which are concentrations of total
protein, albumin, fibrinogen, C-reactive protein (CRP) as well as the immunoglobulins G
(IgG) and M (IgM).
2.5. Erythrocyte 3D Recordings and Shape Classification
Approximately 5 µL of blood was placed into 1 mL of 0.1% glutaraldehyde (Sigma
Aldrich, St. Louis, MO, USA) solution in phosphate-buffered saline (PBS) in order to fix the
shape of the red cells [14]. Erythrocytes (5 µL in 1 mL PBS) were stained with 5 µL of Cell-
Mask Deep Red plasma membrane stain (0.5 mg/mL; Thermo Fisher Scientific, Waltham,
MA, USA) for 24 h at room temperature. Subsequently, the cells were washed 3 times
by centrifugation at 4000× g for 5 min (Eppendorf Micro Centrifuge 5415 C, Brinkmann
Instruments, Riverview, FL, USA) in 1 mL of PBS solution. After washing, the cells were
resuspended in PBS and finally placed on a glass slide for confocal microscopy [15]. Each
labeled sample was placed between two glass slides for imaging (VWR rectangular cover
glass, 24 × 60 mm2) by employing a piezo stepper for a 20 µm z-range. Confocal image
generation was performed with a spinning disk-based confocal head (CSU-W1, Yokogawa
Electric Corporation, Musashino, Japan). Image sequences were acquired with a digital
camera (Orca-Flash 4.0, Hamamatsu Photonics, Hamamatsu City, Japan). A custom-written
MATLAB routine was used to crop single cells from each image and perform 3D recon-
struction to enable visualization of the 3D shapes of the cells. Each single-cell 3D image
contained 68 individual planes with an extent of 100 pixels by 100 pixels and a lateral
(x/y) size of 0.11 µm/pixel. The piezo stepper had a minimal step width of 0.3 µm, defin-
ing the z-plane distance. To compensate for the difference in resolution in the x/y and
z-directions, we modified the z-scale by means of linear interpolation. Thus, the obtained
z-stack had dimensions of 100 × 100 × 185 voxels. The image stacks were then passed to a
custom-written ImageJ script. By applying a fixed threshold for every image, the script
binarized the confocal z-stack to retrieve the cell membrane as an isosurface. Based on these
iso-surface images, an artificial neuronal network was used to classify the cell shapes, as
Biomolecules 2021, 11, 727 4 of 14
recently described [16]. This classification was based on spherical harmonics and allowed
a completely unbiased cell classification.
2.6. Microfluidic Measurements
The microfluidic measurements were performed by applying a set of discrete pressure
drops in a regime up to 700 mbar to a connected Eppendorf tube containing the final
blood solution [17]. To obtain this final blood solution, a volume of 10 µL of RBCs washed
(centrifugation at 1500× g for 5 min) 3 times in PBS was filled to 1 mL total volume with a
solution of PBS and 1 mg/mL bovine serum albumin (BSA), yielding a hematocrit of 1%.
We advected this solution through microfluidic channels with a cross-section of a width of
12 µm, a height of 10 µm and a length of approximately 4 cm.
The flowing RBCs were recorded with a brightfield microscope equipped with an
oil-immersion objective (Plan Apo 60 ×, Nikon, Tokyo, Japan) at a distance 10 mm away
from the channel entrance to avoid the recording of transient cell shapes [18,19]. With the
aid of a custom-tailored particle tracking algorithm, we extracted cropped images of single
flowing RBCs together with their individual velocities and centroid positions.
Cells flowing due to a distinct pressure drop were grouped, and from this set, the
mean velocity was obtained. Analogously, cells associated to one distinct pressure drop
were manually categorized into the scheme of croissants, slippers and acanthocytes [20].
We analyzed the fraction of RBCs obeying healthy morphologies (i.e., slippers and
croissants) and acanthocytes. Based on this classification, we fit the deformed acanthocytes
fraction, ϕAc, heuristically with an exponential decay, according to ϕAc(v) = N0 exp(dv),
with the velocity, v, and fit parameters N0 and d. N0 hereby defines the total fraction of
deformed acanthocytes in stasis, and d is a deformability parameter.
2.7. Aggregate 2D Simulatioons
Two-dimensional (2D) simulations were used to study changes in characteristic hole
sizes between aggregated cells for various mixtures of healthy erythrocytes, rigidified
discocytes and acanthocytes, as hole sizes determine aggregate permeability. A ring-like
bead-spring model with 50 vertices has been employed to represent both discocyte and
acanthocyte (a flower-like shape with six rounded corners) shapes. Note that the ring
circumference is the same for both shapes, while the enclosed area differs. The total
potential energy of the RBC model includes three parts: (i) elastic energy of springs that
sequentially connect all vertices into a ring-like configuration, (ii) bending energy between
two neighboring springs to represent cell bending rigidity and (iii) an area constraint
to enforce the discocyte shape for a fixed circumference [21,22]. Spring rigidity was set
sufficiently large, such that membrane stretching can be neglected. The bending rigidity
for healthy discocytes was equal to 50 kBT, and for rigidified discocytes, to 500 kBT. The
acanthocyte shapes were assumed to be fully rigid.
Langevin dynamics with kBT = 1 has been employed to simulate aggregation of RBCs
within a periodic domain of size 300 × 300 µm2. Lennard–Jones potential, U(r) = 4ε((σ/r)12
− (σ/r)6) for r < rcut with σ = 0.3 µm and rcut = 0.72 µm, was used to implement aggregation
interactions between cells. The strength of the potential, ε, was varied within the range
of 0–3 kBT in different simulations to represent various aggregation strengths. The total
hematocrit was set to ϕ = 50% in all simulations.
2.8. Statistical Analysis
Statistical analysis was performed in Prism8 (GraphPad Software Inc., San Diego, CA,
USA). All datasets were checked for normality of the distribution with the Shapiro–Wilk
test. Statistical differences were evaluated with the Kruskal–Wallis test (characteristic
hole size) or an unpaired Student’s t-test (transition point). The significance of p-values is
abbreviated as ns (not significant) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001
and **** for p < 0.0001.
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3. Results
3.1. The Dasatinib Off-Label Treatment
The results we report rely on a dasatinib off-label treatment of two genetically con-
firmed ChAc patients (P1 and P2 in Supplemental Table S1), which was performed at the
end of 2019 (DRKS00023177). The evaluation and protocol of an initial treatment period
with 100 mg dasatinib/day was previously published [6]. Due to mild gastrointestinal side
effects [7], a second treatment period for almost six months with a reduced dose (from
100 to 80 mg/day) was performed accordingly. This was at a time when we initially started
the measurements of the erythrocyte sedimentation rate (ESR) of neuroacanthocytosis
syndrome (NAS) patients [10]. Therefore, we do not have pretreatment measurements but
two different after-treatment time points. The timeline of the treatment and the sampling
time points are given in Figure 1.
We do not know if dasatinib has a direct effect on the mature red blood cells (RBCs)
or if it acts exclusively on erythropoiesis [7], which would not be unusual for drugs that
manipulate kinase activity [23]. Therefore, we provide an estimation of the portion of
RBCs in the circulation which were ‘produced’ in the presence of dasatinib (grey curve
in Figure 1). This is based on the observation of in vivo cohort labeling experiments [24].
When glycine containing a rare isotope is orally administered, RBCs containing the labelled
glycine appear in the circulation about 15 days later and show an average lifetime of
115–120 days [24]. As a result, the portion of RBCs formed under dasatinib treatment is
similar for the sampling during dasatinib treatment and the first sampling after treatment
(dashed line in Figure 1).

















post treatment periodsampling time point
sampling time point




Figure 1. The course of the off-label treatment of two ChAc patients with dasatinib. The diagram
depicts the temporal information of the treatment with the sampling time points of the measure-
ments performed within this study. The insert shows the structural formula of the Lyn-kinase
inhibitor dasatinib.
3.2. Determination of the Erythrocyte Sedimentation Parameters
Since the ESR was proposed as a biomarker for NAS treatments [10], we performed
ESR measurements technically identical with the initial report [10] and present the results
in Figure 2. This includes the sedimentation curves (Figure 2A), the sedimentation height
at 2 h of sedimentation (Figure 2B) and examples of micrographs showing the RBC ag-
gregate formation on a coverslip with a hematocrit in the 2D layer of approximately 45%
(Figure 2C). We show the latter because hole size (the area of the ‘compartments’ between
the RBCs) was shown to correlate with the ESR [10], and we refer to it below.
For both patients, the ESR performed under dasatinib is higher (towards control
samples) than at 295 days after the end of dasatinib treatment. This increase was on
average 134% for P1 and 104% for P2.
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Figure 2. Measurements of the ESR with the standard Westergren method using EDTA blood. (A) Plots of the color-coded
sedimentation curves retrieved from optical images taken every minute, i.e., the density of the data points corresponds
approximately to the printed resolution. (B) Comparison of the sedimentation height after 2 h, which was proposed to
be a diagnostic biomarker [10]. Please note that panels (A,B) are logarithmic plots. (C) Representative micrographs of
sedimented RBCs forming aggregates on a coverslip. RBC are diluted in plasma, forming a hematocrit of approximately
45% in the 2D layer on the coverslip. The cyan-framed area is an example to indicate a ‘hole’.
3.3. Evaluation of Clinical Laboratory Parameters
To complement the ESR measurements and to identify putative causes for differences
in the ESR, we documented standard clinical laboratory parameters since both RBC (Sup-
plemental Figure S1A–F) and plasma properties (Supplemental Figure S1G–L) contribute
to slow sedimentation in NAS patients [10]. The diagrams in Supplemental Figure S1 show
the selected parameters for all three sampling time points of the two ChAc patients inves-
tigated, with the blue dotted and dashed lines indicating the upper and lower reference
values, respectively.
Since there are only single measurements, there is no option for statistical comparison.
However, most parameters are within the reference value range and do not present obvious
deviations along the three time points. Only P1 is slightly below the lower reference value
for total protein and IgG, but these parameters do not explain the differences in ESR. Al-
though, within the reference range, the C-reactive protein values obey temporal variations,
which are not likely to explain any changes in the RBC sedimentation behavior [25].
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3.4. Erythrocyte Shape Classification
For shape classification of RBCs, we performed confocal imaging and 3D render-
ing [10], with results shown in Figure 3A, that presents acanthocytes (left column) in
comparison to echinocytes (right column). The discrimination between acanthocytes and
echinocytes can be challenging and is, therefore, error-prone and likely to be biased [8,10].
Thus, we used an artificial neural network (ANN) to classify cells in an unbiased, auto-
mated manner [16]. Results are shown in Figure 3B. The left part shows the first step
of the classification into seven distinct classes, with acanthocytes highlighted with an
orange dotted frame. SDE refers to the physiological range stretching from spherocytes
and stomatocytes to discocytes and echinocytes [26], see below. Further classes are: kera-
tocytes, knizocytes (also known as trilobes) [27], multilobate cells, unknown shapes and
cell clusters. The right part of Figure 3B shows the distribution of the SDE shapes on a
continuous scale from –1 to 1, indicating the correlation between the scaling number and
the particular cell shape at the bottom of the panel. The dashed line presents the mean
value (µ), and the dark grey range indicates the confidence interval (CI).
The representative control donor (data shown at the top of Figure 3B) shows predomi-
nantly discocytes (µ close to 0), and the pooled controls of 10 healthy donors show exactly
the same properties, with the exception that the confidence interval is a bit larger. For the
ChAc patients, the acanthocyte number is higher than in controls, but this also applies to
other pathological shapes such as the keratocytes and cells that are classified as unknown
due to their unusual morphology.
When comparing the different sampling time points of both patients, we noticed the
highest acanthocyte count for the final time point 295 days after the end of the dasatinib
treatment. Furthermore, it seems that the CI for the SDE distribution at the last sampling
time point (without the influence of dasatinib) is broader than for the previous samples
(including the representative control).
In Figure 3C, the acanthocyte number was plotted against ESR, showing no correlation
(R2 = 0.02). Nevertheless, it is remarkable that P1, who showed exactly the same ESR twice,
displayed also almost identical acanthocyte counts.
3.5. Modeling of RBC Aggregation
We performed mathematical modeling in order to better understand the contribution
of RBC rigidity and shape to the ESR. Traditionally, inflammation and hence an increase in
certain plasma proteins, mainly fibrinogen, increases RBC interaction forces, which lead
to larger aggregates (conventional view [28]) or increased gel porosity (colloidal physics
interpretation [10]) and therefore, result in an increased ESR. Using 2D simulations of
aggregating RBCs, Figure 4A shows an increased hole size (increased ESR) with increasing
interaction energy. Due to an increase in interaction forces, the cells deform and establish
more compact aggregated structures, resulting in an increase of characteristic hole sizes.
Figure 4B represents similar simulations for mixtures of healthy erythrocytes and
different fractions of rigid acanthocytes. Interestingly, already at 20% of abnormal cells, the
characteristic hole size is significantly smaller than that of the healthy case, resulting in
decreased ESR. This situation well-reflects our previously reported inverse correlation of
acanthocyte number and ESR [10].
Finally, Figure 4C shows simulation results, where rigid acanthocytes are replaced by
rigidified discocyte cells, and demonstrates that the shape of the acanthocytes has very little
influence on hole size. Instead, it is the increased rigidity that leads to very similar values
in hole size compared to Figure 4B. For illustration, panels D and E show representative
images corresponding to the conditions plotted in panels B and C, respectively.
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Figure 3. Classification of RBC morphology by an artificial neural network (ANN). (A) Panel A shows 3D-rendered RBCs
based on confocal stack recordings. We present the comparison of acanthocytes on the left and echinocytes on the right, as
classified by the ANN. (B) Panel B depicts the quantification of the morphological classification for a representative healthy
control, a pooled control of 10 donors and the two ChAc patients for the three sampling time points. (C) In panel C, the
acanthocyte number is plotted against the ESR for the two ChAc patients. There is no correlation between the parameters
(slope of the linear regression is not significantly different from zero (p = 0.8)).
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20% acanthocytes 20% rigidified cells
Figure 4. 2D modeling of RBC aggregation to better understand the dependence of characteristic hole size on the aggregation
strength and fraction of acanthocytes. The larger the hole size, the faster the ESR. (A) Panel A shows hole sizes when only
the interaction energy varies. An increase in the interaction energy mimics an increase in the plasma protein concentration,
mainly the fibrinogen. (B) Panel B represents the situation of a variable number of acanthocytes, whereas acanthocytes
have a different shape and are completely rigid. (C) Panel C depicts the situation when the interaction energy is constant,
and all cells have the same discocyte shape, but the number of rigidified cells increases. ** refers to a significance level of
p < 0.01, *** to p < 0.001 and **** to p < 0.0001. The abbreviation ns stands for not significant. (D,E) are example images for
20% acanthocytes and 20% rigidified cells respectively, as presented in panels (B,C). For a better visualization, the holes are
marked in a variety of false colors. The scale bar refers to 100 µm.
3.6. Erythrocyte Phase Diagram-Derived Parameters
Since the theoretical modeling revealed that for a decreased ESR, the rigidity of the
RBCs is more important than the cell shape, we wanted to have a closer look at the healthy-
looking RBCs (normocytes), which form croissant and slipper shapes in microfluidic
flow [20]. We were especially interested in whether there was a difference in the rigidity of
normocytes comparing ChAc patients (without dasatinib treatment) and healthy controls
(for a detailed patient description, see Supplemental Table S1).
Figure 5A presents representative images of the normocyte cell shapes of crois-
sants and slippers (left images) in comparison to the acanthocytes in flow (right images).
Figure 5B shows the phase diagram of the cell shapes (croissants, slippers and acantho-
cytes) as a function of the flow velocity in the microfluidic channel for a representative
healthy control (left) and a representative ChAc patient (right). In the control, no acan-
thocytes were detected. However, in both cases, the number of croissants increases for
increasing flow velocity, while the number of slippers decreases. If RBCs have an increased
Biomolecules 2021, 11, 727 10 of 14
rigidity (decreased deformability), increased flow stresses (or larger flow velocities) are
required for the transition from croissants to slippers. To obtain a quantitative measure of
this transition independently of the total number of cells, we define the transition point
as the speed when the number of croissants equals the number of slippers. To avoid the
influence of errors in single measurement points, we performed a fit on all points within
the exponential decay or the exponential growth of the croissants and slippers respectively,
and determined the transition point as the intersection of the fitting curves (brown circles
in Figure 5B). The statistical comparison of 6 ChAc patients and 7 healthy controls revealed
a significant difference, as shown in Figure 5C. This indeed indicated a difference in the
deformability, such that normocytes of ChAc patients are on average less deformable than
those for healthy controls.
















































































Figure 5. Investigation of RBC shapes in microfluidic flow. (A) Panel A shows the flow shapes of
healthy RBCs (normocytes) on the left and a variety of acanthocytes on the right. (B) Panel B compares
representative phase diagrams of a healthy control donor on the left and an (untreated) ChAc patient
on the right, with the fitted exponential changes in the cell numbers. The transition point, where the
number of croissants and slippers is identical, is marked with brown circles. (C) Panel C compares
the transition points of a cohort of healthy controls and untreated ChAc pa-tients, indicating a higher
rigidity of the normocytes in ChAc patients. * refers to a significance level of p < 0.05. (D) Panel D
depicts the variance of the deformation parameter, d, of the acan-thocytes of different donors in flow.
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Furthermore, we performed an exponential fit on the fraction of acanthocytes in the
phase diagram of the ChAc patients. This deformation parameter, d, indicates the rigidity
of the acanthocytes. The plot of the d-value in Figure 5D shows the tremendous variability
of the parameter (approximately factor of 4), indicating a significant variation in the rigidity
of the acanthocytes among the ChAc patients.
4. Discussion
To summarize the results, the mechano-morphological characterization of RBCs from
two ChAc patients in an off-label treatment with dasatinib revealed differences in the
ESR and the acanthocyte count during and after the treatment period, which could not be
directly related to each other. Mathematical modeling indicated that RBC rigidity is more
important for delayed ESR than cell shape. Microfluidic experiments confirmed a higher
rigidity in the normocytes of ChAc patients compared to healthy controls.
It is still not quite clear if dasatinib affects only RBC formation during erythropoiesis or
also mature RBCs. Although there is clear evidence for processes manipulated by dasatinib
during erythropoiesis [4], it is not entirely clear to what extent these putative alterations
are reflected in the mature RBCs properties. With the study design used here (Figure 1), we
cannot finally elucidate these effects, since our measurements are too sparse.
For the ESR, we see a compatibility between the measured values and the concept
that the ESR could be a biomarker, along with other markers reflecting the disease’s mani-
festation in the central and peripheral nervous system, such as serum neurofilament [29],
for treatment response. This is again with the reservation of an unknown relationship
between hematological and neurological phenotype. Therefore, it is imperative to combine
peripheral markers like the ESR with clinical and paraclinical parameters of the nervous
system [6]. However, the differences detected in the ESR are not very large and the nature
of an off-label treatment with two patients is not suited to provide a statistical evaluation
allowing for significance testing. Further trials are required to validate the usefulness as
biomarkers. Independent of that, we looked for possible reasons for the difference in the
measured ESRs of the two ChAc patients, which can be caused by plasma parameters as
well as by RBCs properties [10]. To this end, we performed measurements of a variety of
clinical parameters (Supplemental Figure S1). Almost all values remain within the reference
range and none of them were suitable to explain the differences in the ESR. Especially, the
fibrinogen concentration, which is known to stabilize the RBC clusters in both stasis and
flow [30,31], does not correlate with the ESR.
Although there is no correlation between the ESR and the acanthocyte count (Figure 3C),
the comprehensive analysis (Figure 3B) revealed several interesting aspects. It is not just
the acanthocytes that are increased in the ChAc patients (in general), but also the kerato-
cytes and the ‘unknown shapes’. Although the network was trained carefully [16], future
refinements may decrease the number of ‘unknown shapes’. Even more interesting is the
RBC shape distribution among the SDE scale. Here, the ChAc patients’ samples with RBCs
formed under dasatinib treatment showed a clearly narrower confidence interval than
at the last sampling time point (no RBCs formed under dasatinib treatment). This is in
principle in line with the measured ESR, but again it is just an initial evidence which still
needs to be statistically proven. However, it is clear that RBC properties in ChAc patients
need to be considered in a more holistic manner and not just in terms of acanthocyte counts.
Along this line, we performed mathematical modeling to dissect the contributions
of RBCs shape and rigidity to a decreased ESR (Figure 4). The model is based on our
previous work, where we could correlate the hole size in the structure of aggregating
RBCs in 2D to the ESR (both in experiments and the theoretical model) [10]. Here, we
showed that the rigidity of the RBCs is the dominating parameter and RBCs shape plays
just a minor role. To this end, an influence of dasatinib on the cell rigidity would also be
plausible. Dasatinib inhibits Lyn-kinase, which phosphorylates Band3 protein. Since Band3
protein is a structural protein, connecting the RBC membrane and the cytoskeleton [32], a
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reduction of the hyperphosphorylation of Band3 protein (towards ‘normal’ RBC conditions)
by dasatinib would fit well into the overall picture.
Since it is known that acanthocytes have an increased rigidity [33], in our microfluidic
experiments, we focused on the rigidity of the normocytes. To this end, we analyzed the
transition of cell shapes from croissants to slippers in a group of seven ChAc patients (no
dasatinib treatment) and seven healthy controls. A significant shift in the transition point
was found (Figure 5C), confirming a higher rigidity of the normocytes in the ChAc patients.
This latter outcome was not investigated in dependence of the dasatinib treatment.
5. Conclusions
In this paper, we characterized the mechano-morphological properties of RBCs from
two ChAc patients under treatment with dasatinib. Although this provided some insights
into the role of acanthocytes and their associated properties in the ESR, the data are too
sparse/preliminary to answer the question of whether the ESR is a suitable biomarker to
follow treatment.
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